Persistence of minimal residual disease in bone marrow
predicts outcome in follicular lymphomas treated with a
rituximab-intensive program
by Marco Ladetto, Chiara Lobetti-Bodoni, Barbara Mantoan, Manuela Ceccarelli,
Carola Boccomini, Elisa Genuardi, Annalisa Chiappella, Luca Baldini, Giuseppe
Rossi, Alessandro Pulsoni, Francesco Di Raimondo, Luigi Rigacci, Antonello Pinto,
Sara Galimberti, Alessia Bari, Delia Rota-Scalabrini, Angela Ferrari, Francesco Zaja,
Andrea Gallamini, Giorgina Specchia, Pellegrino Musto, Francesca Gaia Rossi,
Enrica Gamba, Andrea Evangelista, and Umberto Vitolo
Blood
Volume 122(23):3759-3766
November 28, 2013
©2013 by American Society of Hematology
Study plan for MRD analysis.
Marco Ladetto et al. Blood 2013;122:3759-3766
©2013 by American Society of Hematology
Descriptive results of bcl-2/IgH PCR analysis.
Marco Ladetto et al. Blood 2013;122:3759-3766
©2013 by American Society of Hematology
Time-varying covariate model of accumulation of PCR-negative findings.
Marco Ladetto et al. Blood 2013;122:3759-3766
©2013 by American Society of Hematology
Effect of MRD by response status and treatment group.
Marco Ladetto et al. Blood 2013;122:3759-3766
©2013 by American Society of Hematology